TY - JOUR
T1 - European guideline (EuroGuiDerm) on atopic eczema
T2 - part I – systemic therapy
AU - Wollenberg, A.
AU - Kinberger, M.
AU - Arents, B.
AU - Aszodi, N.
AU - Avila Valle, G.
AU - Barbarot, S.
AU - Bieber, T.
AU - Brough, H. A.
AU - Calzavara Pinton, P.
AU - Christen-Zäch, S.
AU - Deleuran, M.
AU - Dittmann, M.
AU - Dressler, C.
AU - Fink-Wagner, A. H.
AU - Fosse, N.
AU - Gáspár, K.
AU - Gerbens, L.
AU - Gieler, U.
AU - Girolomoni, G.
AU - Gregoriou, S.
AU - Mortz, C. G.
AU - Nast, A.
AU - Nygaard, U.
AU - Redding, M.
AU - Rehbinder, E. M.
AU - Ring, J.
AU - Rossi, M.
AU - Serra-Baldrich, E.
AU - Simon, D.
AU - Szalai, Z. Z.
AU - Szepietowski, J. C.
AU - Torrelo, A.
AU - Werfel, T.
AU - Flohr, C.
N1 - Funding Information:
Open Access funding enabled and organized by Projekt DEAL.
Publisher Copyright:
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2022/9
Y1 - 2022/9
N2 - The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.
AB - The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.
KW - atopic dermatitis
KW - atopic eczema
UR - http://www.scopus.com/inward/record.url?scp=85135879234&partnerID=8YFLogxK
U2 - 10.1111/jdv.18345
DO - 10.1111/jdv.18345
M3 - Article
AN - SCOPUS:85135879234
SN - 0926-9959
VL - 36
SP - 1409
EP - 1431
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 9
ER -
